Similar articles for PMID: 29311124

Year	Number of Results
1994	1
1995	1
1996	2
1997	2
1999	1
2000	2
2001	5
2002	1
2003	5
2004	5
2005	7
2006	6
2007	4
2008	9
2009	4
2010	6
2011	6
2012	6
2013	6
2014	12
2015	7
2016	5
2017	6
2018	2
2019	2
2020	6
2021	11
2022	5
2023	1
2024	0

1

Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Jakimovski D, et al. Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003. Cold Spring Harb Perspect Med. 2018. PMID: 29311124 Free PMC article. Review.

2

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

Nikfar S, Rahimi R, Abdollahi M. Nikfar S, et al. Clin Ther. 2010 Oct;32(11):1871-88. doi: 10.1016/j.clinthera.2010.10.006. Clin Ther. 2010. PMID: 21095482 Review.

3

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis.

Vartanian T. Vartanian T. Clin Ther. 2003 Jan;25(1):105-18. doi: 10.1016/s0149-2918(03)90013-0. Clin Ther. 2003. PMID: 12637114 Review.

4

IFN-β and multiple sclerosis: from etiology to therapy and back.

Annibali V, Mechelli R, Romano S, Buscarinu MC, Fornasiero A, Umeton R, Ricigliano VA, Orzi F, Coccia EM, Salvetti M, Ristori G. Annibali V, et al. Cytokine Growth Factor Rev. 2015 Apr;26(2):221-8. doi: 10.1016/j.cytogfr.2014.10.010. Epub 2014 Oct 31. Cytokine Growth Factor Rev. 2015. PMID: 25466632 Review.

5

Interferon-beta1b for the treatment of multiple sclerosis.

Lam S, Wang S, Gottesman M. Lam S, et al. Expert Opin Drug Metab Toxicol. 2008 Aug;4(8):1111-7. doi: 10.1517/17425255.4.8.1111. Expert Opin Drug Metab Toxicol. 2008. PMID: 18680445 Review.

6

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. He D, et al. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Cochrane Database Syst Rev. 2012. PMID: 23235682 Updated. Review.

7

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.

Cohen BA, Rivera VM. Cohen BA, et al. Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Curr Med Res Opin. 2010. PMID: 20121658 Review.

8

Interferon-beta1a for the treatment of multiple sclerosis.

Clerico M, Contessa G, Durelli L. Clerico M, et al. Expert Opin Biol Ther. 2007 Apr;7(4):535-42. doi: 10.1517/14712598.7.4.535. Expert Opin Biol Ther. 2007. PMID: 17373904 Review.

9

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Goldberg LD, et al. J Manag Care Pharm. 2009 Sep;15(7):543-55. doi: 10.18553/jmcp.2009.15.7.543. J Manag Care Pharm. 2009. PMID: 19739877 Free PMC article.

10

Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

McCormack PL, Scott LJ. McCormack PL, et al. CNS Drugs. 2004;18(8):521-46. doi: 10.2165/00023210-200418080-00004. CNS Drugs. 2004. PMID: 15182221 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

130 results

Results by year